In the current era of immunotherapy successes, Min and colleagues report the promising preclinical development and efficacy of a CAR T cell therapy that recognizes ICAM-1, which is highly expressed in advanced thyroid cancers. Herein, we discuss the feasibility of this approach and its implications for future therapies to treat thyroid cancer.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Han, E. Q., et al. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J. Hematol. Oncol. 6, 47 (2013).
Maus, M. V. et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625–2635 (2014).
Min, I. M. et al. CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-17-2008 (2017).
van de Stolpe, A. & van der Saag, P. T. Intercellular adhesion molecule-1. J. Mol. Med. 74, 13–33 (1996).
Pasieka, Z. et al. Soluble intracellular adhesion molecules (sICAM-1, sVCAM-1) in peripheral blood of patients with thyroid cancer. Neoplasma 51, 34–37 (2004).
Haug, C. E. et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 55, 766–773 (1993).
Holzinger, A. & Abken, H. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target. Cancer Immunol. Immunother. 66, 1505–1507 (2017).
Park, S. et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci. Rep. 7, 14366 (2017).
Rafiq, S. et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen. Leukemia 31, 1788–1797 (2017).
Bhoj, V. G. et al. GDNF family receptor alpha 4 (GFRa4)-targeted adoptive T-cell immunotherapy for medullary thyroid carcinoma [abstract]. Cancer Res. 76 (Suppl.), 2295 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors have received research support from Merck and Eisai for a phase II clinical trial investigating lenvatinib and pembrolizumab in treating patients with advanced differentiated thyroid cancer.
Rights and permissions
About this article
Cite this article
French, J., Haugen, B. CAR T cell therapy — potential in advanced thyroid cancer?. Nat Rev Endocrinol 14, 10–11 (2018). https://doi.org/10.1038/nrendo.2017.160
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2017.160
